BIONDVAX PHARMACEUTICALS-ADR (BVXV) Stock Balance Sheet
NASDAQ:BVXV - Nasdaq - US09073Q2049 - ADR - Currency: USD
| 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | 2017 (2017-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 14.28M | 9.40M | 72.50M | 75.90M | 71.40M | |||
| Marketable Securities | N/A | N/A | N/A | N/A | 0.00 | |||
| Receivables | 267.50K | 1.20M | 700.00K | 1.00M | 3.90M | |||
| Total Current Assets | 14.55M | 10.60M | 73.10M | 76.80M | 75.30M | |||
| Non-Current Assets | ||||||||
| PPE Net | 11.66M | 45.80M | 42.10M | 28.20M | 5.50M | |||
| Investments And Advances | N/A | N/A | N/A | N/A | 0.00 | |||
| Other Non-Current Assets | 117.36K | 500.00K | 500.00K | 700.00K | 900.00K | |||
| Total Non-Current Assets | 11.78M | 46.30M | 42.70M | 29.00M | 6.40M | |||
| TOTAL ASSETS | 26.33M | 56.90M | 115.80M | 105.80M | 81.70M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 60.40M | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 773.00K | 700.00K | 700.00K | N/A | N/A | |||
| Accrued Expenses | 204.33K | N/A | N/A | N/A | N/A | |||
| Accounts Payable | 1.70M | 3.10M | 18.30M | 21.80M | 6.90M | |||
| Total Current Liabilities | 1.91M | 64.20M | 19.00M | 21.80M | 6.90M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 18.23M | 6.10M | 130.60M | 94.40M | 0.00 | |||
| Other Non-Current Liabilities | 25.11K | 1.20M | 31.30M | 20.90M | 18.60M | |||
| Total Non-Current Liabilities | 18.25M | 7.30M | 161.80M | 115.30M | 18.50M | |||
| TOTAL LIABILITIES | 20.16M | 71.50M | 180.80M | 137.10M | 25.40M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -96.42M | -324.80M | -320.30M | -211.10M | -123.40M | |||
| Additional Paid In Capital | 102.59M | 310.20M | 255.30M | 179.90M | 179.70M | |||
| Common Shares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Shares Outstanding | 2.08M | 1.30M | 1.13M | 737.00K | 737.00K | |||
| Tangible Book Value per Share | 0.01 | -0.03 | -0.16 | -0.12 | 0.22 | |||
| Total Shareholders' Equity | 6.17M | -14.60M | -65.10M | -31.20M | 56.30M | |||
| TOTAL LIABILITIES AND EQUITY | 26.33M | 56.90M | 115.80M | 105.80M | 81.70M | |||
| Statistics | ||||||||
| Debt/Equity | 2.96 | -4.55 | -2.01 | -3.03 | N/A | |||
| Current Ratio | 7.64 | 0.17 | 3.85 | 3.52 | 10.91 | |||
| Return On Assets (ROA) | -41.49% | -7.84% | -94.29% | -82.92% | -42.29% | |||
| Return On Equity (ROE) | -177.10% | N/A | N/A | N/A | -61.37% | |||
| Return On Invested Capital (ROIC) | N/A | 10.91% | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | 13.25% | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | N/A | 13.25% | N/A | N/A | N/A | |||
All data in USD , ROIC based on taxRate of 0.21